84 filings
Page 2 of 5
SC TO-T
drkh3bqcwm4 18u
10 Jan 24
Third party tender offer statement
8:51am
SC14D9C
mny3cyh
22 Dec 23
Written communication relating to third party tender offer
6:52am
8-K
y1l7evut0vf8z
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
ygz83jso
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
hbjd1yp2md pdp5zy2
27 Nov 23
Other Events
6:37am
NT 10-Q
x6s6 bekyem6eks
15 Nov 23
Notice of late quarterly filing
7:00am
8-K
1pgzhgsm
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
8-K
s7a4m0i4fmhmz 0g41
31 Oct 23
Termination of a Material Definitive Agreement
4:13pm
8-K
rrqvjlk4rffjvnuaackx
10 Aug 23
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
7:05am
8-K
keln 125c
13 Jul 23
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
4:08pm
8-K
qrhdr7z 47a
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:32pm
8-K
7pch1vg
25 May 23
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
5:04pm
8-K
v0gmt5q4cmm
11 May 23
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
7:09am
ARS
3tsyzm6e
26 Apr 23
Annual report to shareholders
9:03am
DEFA14A
6bxv4mb4toy6rkuek
26 Apr 23
Additional proxy soliciting materials
9:01am
PRE 14A
q51ozsh53jkl ui
14 Apr 23
Preliminary proxy
9:00am